Off-market insider net buying at Helix BioPharma (T:HBP)

Jerzy Wilczewski, a 10% Holder, acquired 13,725,500 Common Shares on a direct ownership basis at a price of $0.455 through a prospectus or prospectus exempt offering on August 21st, 2019. The insider also acquired 13,725,500 Warrants with an exercise price of $0.720 for 5 long years. This represents a $6,245,102 net investment into the company's shares and an account share holdings change of greater than 100%.

Helix BioPharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).